Latest Insider Transactions at X4 Pharmaceuticals, Inc (XFOR)
This section provides a real-time view of insider transactions for X4 Pharmaceuticals, Inc (XFOR). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of X4 Pharmaceuticals, Inc to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of X4 Pharmaceuticals, Inc's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Nov 15
2024
|
Paula Ragan President and CEO |
SELL
Open market or private sale
|
Direct |
31,897
-3.11%
|
$0
$0.39 P/Share
|
|
Oct 15
2024
|
Paula Ragan President and CEO |
SELL
Open market or private sale
|
Direct |
31,897
-3.02%
|
$0
$0.56 P/Share
|
|
Oct 07
2024
|
Adam S. Mostafa Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
230,645
-100.0%
|
$0
$0.55 P/Share
|
|
Oct 07
2024
|
Arthur Taveras Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
76,920
-16.54%
|
$0
$0.56 P/Share
|
|
Oct 07
2024
|
Mary Di Biase Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
67,695
-13.02%
|
$0
$0.57 P/Share
|
|
Oct 07
2024
|
Paula Ragan President and CEO |
SELL
Open market or private sale
|
Direct |
239,436
-18.46%
|
$0
$0.55 P/Share
|
|
Oct 07
2024
|
Mark Baldry Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
11,127
-18.66%
|
$0
$0.58 P/Share
|
|
Oct 04
2024
|
Adam S. Mostafa Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
230,645
+50.0%
|
-
|
|
Oct 04
2024
|
Arthur Taveras Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
230,645
+33.16%
|
-
|
|
Oct 04
2024
|
Mary Di Biase Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
230,645
+30.74%
|
-
|
|
Oct 04
2024
|
Paula Ragan President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
532,081
+29.09%
|
-
|
|
Oct 04
2024
|
Mark Baldry Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
34,946
+36.95%
|
-
|
|
Sep 09
2024
|
Mary Di Biase Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
2,642
-0.91%
|
$0
$0.66 P/Share
|
|
Jun 10
2024
|
Michael S Wyzga Director |
BUY
Grant, award, or other acquisition
|
Direct |
45,000
+27.0%
|
-
|
|
Jun 10
2024
|
Alison Frances Lawton Director |
BUY
Grant, award, or other acquisition
|
Direct |
45,000
+31.76%
|
-
|
|
Jun 10
2024
|
Keith Woods Director |
BUY
Grant, award, or other acquisition
|
Direct |
45,000
+25.0%
|
-
|
|
Jun 10
2024
|
Gary Bridger Director |
BUY
Grant, award, or other acquisition
|
Direct |
45,000
+31.76%
|
-
|
|
Jun 10
2024
|
Murray Stewart Director |
BUY
Grant, award, or other acquisition
|
Direct |
45,000
+19.03%
|
-
|
|
Jun 10
2024
|
David W J Mcgirr Director |
BUY
Grant, award, or other acquisition
|
Direct |
45,000
+31.76%
|
-
|
|
Jun 10
2024
|
William Aliski Director |
BUY
Grant, award, or other acquisition
|
Direct |
45,000
+31.76%
|
-
|
|
Jun 10
2024
|
Francoise De Craecker Director |
BUY
Grant, award, or other acquisition
|
Direct |
45,000
+31.76%
|
-
|
|
Mar 11
2024
|
Adam S. Mostafa Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
52,500
-100.0%
|
$0
$0.88 P/Share
|
|
Mar 11
2024
|
Paula Ragan President and CEO |
SELL
Open market or private sale
|
Direct |
49,678
-6.1%
|
$0
$0.88 P/Share
|
|
Mar 11
2024
|
Arthur Taveras Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
14,235
-5.73%
|
$0
$0.88 P/Share
|
|
Mar 11
2024
|
Mary Di Biase Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
15,409
-5.02%
|
$0
$0.88 P/Share
|
|
Feb 12
2024
|
Arthur Taveras Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
787
-0.32%
|
$787
$1.01 P/Share
|
|
Feb 12
2024
|
Mary Di Biase Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
3,683
-1.18%
|
$3,683
$1.01 P/Share
|
|
Feb 12
2024
|
Paula Ragan President and CEO |
SELL
Open market or private sale
|
Direct |
21,695
-2.59%
|
$21,695
$1.01 P/Share
|
|
Feb 12
2024
|
Adam S. Mostafa Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
27,721
-34.56%
|
$27,721
$1.01 P/Share
|
|
Nov 03
2023
|
Paula Ragan President and CEO |
SELL
Open market or private sale
|
Direct |
39,906
-4.55%
|
$0
$0.9 P/Share
|
|
Nov 01
2023
|
Paula Ragan President and CEO |
SELL
Open market or private sale
|
Direct |
199,531
-18.55%
|
$0
$0.73 P/Share
|
|
Nov 01
2023
|
Mark Baldry Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
10,257
-29.35%
|
$0
$0.73 P/Share
|
|
Nov 01
2023
|
Mary Di Biase Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
67,695
-17.88%
|
$0
$0.73 P/Share
|
|
Nov 01
2023
|
Adam S. Mostafa Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
230,645
-74.19%
|
$0
$0.73 P/Share
|
|
Nov 01
2023
|
Arthur Taveras Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
67,695
-21.35%
|
$0
$0.73 P/Share
|
|
Oct 31
2023
|
Mark Baldry Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
34,947
+50.0%
|
-
|
|
Oct 31
2023
|
Adam S. Mostafa Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
230,645
+42.59%
|
-
|
|
Oct 31
2023
|
Mary Di Biase Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
230,645
+37.86%
|
-
|
|
Oct 31
2023
|
Paula Ragan President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
532,081
+33.09%
|
-
|
|
Oct 31
2023
|
Arthur Taveras Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
230,645
+42.11%
|
-
|
|
Oct 16
2023
|
Keith Woods Director |
BUY
Grant, award, or other acquisition
|
Direct |
90,000
+50.0%
|
-
|
|
Sep 08
2023
|
Mary Di Biase Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
2,642
-1.76%
|
$2,642
$1.25 P/Share
|
|
Aug 18
2023
|
Michael S Wyzga Director |
BUY
Open market or private purchase
|
Direct |
25,000
+24.59%
|
$25,000
$1.2 P/Share
|
|
Aug 10
2023
|
Murray Stewart Director |
SELL
Open market or private sale
|
Direct |
130,056
-47.03%
|
$130,056
$1.06 P/Share
|
|
Aug 09
2023
|
Murray Stewart Director |
BUY
Grant, award, or other acquisition
|
Direct |
269,893
+49.39%
|
-
|
|
Jun 30
2023
|
Adam S. Mostafa Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
2,641
-3.19%
|
$2,641
$1.89 P/Share
|
|
Jun 30
2023
|
Mary Di Biase Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
464
-0.31%
|
$464
$1.89 P/Share
|
|
Jun 23
2023
|
Mary Di Biase Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
857
-0.56%
|
$857
$1.93 P/Share
|
|
Jun 23
2023
|
Paula Ragan President and CEO |
SELL
Open market or private sale
|
Direct |
6,724
-1.22%
|
$6,724
$1.92 P/Share
|
|
Jun 23
2023
|
Adam S. Mostafa Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
5,417
-6.14%
|
$5,417
$1.93 P/Share
|